NUTRIBAND INC (NTRB) Fundamental Analysis & Valuation

NASDAQ:NTRB • US67092M2089

Current stock price

4.09 USD
+0.01 (+0.25%)
Last:

This NTRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NTRB Profitability Analysis

1.1 Basic Checks

  • NTRB had negative earnings in the past year.
  • NTRB had a negative operating cash flow in the past year.
  • NTRB had negative earnings in each of the past 5 years.
  • In the past 5 years NTRB always reported negative operating cash flow.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -410.87%, NTRB is doing worse than 94.76% of the companies in the same industry.
  • The Return On Equity of NTRB (-458.24%) is worse than 83.25% of its industry peers.
Industry RankSector Rank
ROA -410.87%
ROE -458.24%
ROIC N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • NTRB's Gross Margin of 33.50% is in line compared to the rest of the industry. NTRB outperforms 57.59% of its industry peers.
  • NTRB's Gross Margin has been stable in the last couple of years.
  • NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NTRB Health Analysis

2.1 Basic Checks

  • NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NTRB has more shares outstanding
  • The number of shares outstanding for NTRB has been increased compared to 5 years ago.
  • NTRB has a better debt/assets ratio than last year.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • An Altman-Z score of 23.99 indicates that NTRB is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 23.99, NTRB belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.01, NTRB is in line with its industry, outperforming 57.59% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 23.99
ROIC/WACCN/A
WACC9.33%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M

2.3 Liquidity

  • A Current Ratio of 7.53 indicates that NTRB has no problem at all paying its short term obligations.
  • NTRB has a better Current ratio (7.53) than 74.87% of its industry peers.
  • A Quick Ratio of 7.35 indicates that NTRB has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.35, NTRB is doing good in the industry, outperforming 74.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.35
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. NTRB Growth Analysis

3.1 Past

  • The earnings per share for NTRB have decreased strongly by -331.58% in the last year.
  • The Revenue has grown by 12.69% in the past year. This is quite good.
  • The Revenue has been growing by 41.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-331.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.78%
Revenue 1Y (TTM)12.69%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%-46.42%

3.2 Future

  • NTRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 100.83% yearly.
  • Based on estimates for the next years, NTRB will show a very strong growth in Revenue. The Revenue will grow by 334.01% on average per year.
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. NTRB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NTRB. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 2.77, the valuation of NTRB can be described as very cheap.
  • 97.91% of the companies in the same industry are more expensive than NTRB, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 37.95. NTRB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 2.77
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • NTRB's earnings are expected to grow with 100.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y110.16%
EPS Next 3Y100.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NTRB Dividend Analysis

5.1 Amount

  • NTRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NTRB Fundamentals: All Metrics, Ratios and Statistics

NUTRIBAND INC

NASDAQ:NTRB (4/16/2026, 4:30:02 PM)

4.09

+0.01 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-11
Earnings (Next)04-27
Inst Owners2.99%
Inst Owner Change0%
Ins Owners59.53%
Ins Owner Change0%
Market Cap49.78M
Revenue(TTM)2.28M
Net Income(TTM)-34.59M
Analysts82.86
Price Target15.3 (274.08%)
Short Float %6.97%
Short Ratio18.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.73%
Min EPS beat(2)-3.81%
Max EPS beat(2)85.27%
EPS beat(4)2
Avg EPS beat(4)-52.18%
Min EPS beat(4)-316.67%
Max EPS beat(4)85.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-31.62%
Min Revenue beat(2)-49.75%
Max Revenue beat(2)-13.5%
Revenue beat(4)0
Avg Revenue beat(4)-19.02%
Min Revenue beat(4)-49.75%
Max Revenue beat(4)-1.6%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2.77
P/S 21.85
P/FCF N/A
P/OCF N/A
P/B 6.59
P/tB 8.87
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)1.48
Fwd EY36.16%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.19
BVpS0.62
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -410.87%
ROE -458.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.5%
FCFM N/A
ROA(3y)-86.9%
ROA(5y)-68.06%
ROE(3y)-100.18%
ROE(5y)-79.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5YN/A
F-Score5
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.3%
Cap/Sales 0.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.35
Altman-Z 23.99
F-Score5
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-331.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-161.78%
EPS Next Y-933.33%
EPS Next 2Y110.16%
EPS Next 3Y100.83%
EPS Next 5YN/A
Revenue 1Y (TTM)12.69%
Revenue growth 3Y14.58%
Revenue growth 5Y41.99%
Sales Q2Q%-46.42%
Revenue Next Year23.72%
Revenue Next 2Y557.52%
Revenue Next 3Y334.01%
Revenue Next 5YN/A
EBIT growth 1Y-53.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-55.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.72%
OCF growth 3YN/A
OCF growth 5YN/A

NUTRIBAND INC / NTRB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NUTRIBAND INC?

ChartMill assigns a fundamental rating of 4 / 10 to NTRB.


What is the valuation status for NTRB stock?

ChartMill assigns a valuation rating of 3 / 10 to NUTRIBAND INC (NTRB). This can be considered as Overvalued.


What is the profitability of NTRB stock?

NUTRIBAND INC (NTRB) has a profitability rating of 1 / 10.


Can you provide the financial health for NTRB stock?

The financial health rating of NUTRIBAND INC (NTRB) is 5 / 10.